AURORA, Colo., Sept. 27 /PRNewswire/ — The Colorado Institute
for Drug, Device and Diagnostic Development (CID4) has completed
the selection process from its first solicitation announced in
February.  The announcement is made by Richard C. Duke, Ph.D.,
CID4 President/CEO, who says, “Boulder-based Sophono, Inc., is
receiving $600,000 for its Alpha 1 Magnetic Bone Anchored Hearing
System; and Aurora-based PeptiVir, Inc., is receiving $300,000 for
its universal flu vaccine under development.”

In addition to initial financial support from the state, CID4
also received federal support from Fitzsimons Redevelopment
Authority via a Senate appropriation supported by Colorado Senator
Michael Bennet.  Senator Bennet says, “We can strengthen our
economic recovery and ensure Colorado remains a leader in
innovation and entrepreneurship by supporting efforts that turn
groundbreaking research into startups and companies that will grow
and create good-paying jobs.”

Further, Colorado Governor Bill Ritter, says: “Supporting
Colorado’s life sciences companies is critical to growing jobs and
our economy in Colorado, and I congratulate both the CID4 for
success in its first solicitation and those companies chosen to
receive funding.”

“Sophono’s Alpha 1 has received its CE mark and is being sold in
Europe.  Our investment will allow Sophono to accelerate its
FDA clearance process,” Kevin M. Smith, CID4 Executive Vice
President/COO, explains. In addition, according to Sophono’s
President/CEO Jim Kasic, the company plans to relocate
manufacturing and assembling operations from Germany to Boulder,
resulting in the hiring of 6-10 employees. Visit http://www.sophono.com.
 

PeptiVir, Inc., is an early stage biopharmaceutical company
focused on the development and commercialization of a
conformationally-constrained, synthetic peptide-based vaccine
platform for prevention of viral diseases.

‘/>”/>

SOURCE